Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR1 | Q8TCW9 | 9/20 | 0.49 |
| ▸ | SCD5 | Q86SK9 | 7/20 | 0.40 |
| ▸ | SCD | O00767 | 6/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15534859 | 0.85 | PROKR1 (0.47) | PROKR1SCD5SCDHDAC3HDAC4 | |
| SCHEMBL23089242 | 0.81 | GABRP (0.45) | PROKR1SCD5SCDUSP30HDAC3 | |
| SCHEMBL16211754 | 0.80 | FFAR1 (0.36) | PROKR1SCD5SCD | |
| SCHEMBL20757641 | 0.79 | PDE4B (0.46) | PROKR1USP30 | |
| SCHEMBL30094557 | 0.79 | PDE4B (0.46) | PROKR1USP30 | |
| SCHEMBL23705987 | 0.79 | USP30 (0.44) | PROKR1SCD5SCDUSP30 | |
| SCHEMBL20743057 | 0.77 | PROKR1 (0.41) | PROKR1USP30 | |
| SCHEMBL23845519 | 0.77 | SLC6A2 (0.40) | PROKR1 | |
| SCHEMBL2720172 | 0.76 | SCD5 (0.49) | SCD5SCD | |
| SCHEMBL162009 | 0.76 | NAPRT (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4121426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | Akebia Therapeutics Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021188938-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-11028085-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists | Nimbus Saturn, Inc. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11021481-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210078996-A1 | HPK1 ANTAGONISTS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028085-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists | HIPK1, PDXK, IP6K1 | PROKR1 425/4885SCD5 3771/4885SCD 3766/4885 |
| US-20210078996-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | PROKR1 239/4885SCD5 2717/4885SCD 2655/4885 |
| US-11021481-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, PDXK, IP6K1 | PROKR1 425/4885SCD5 3771/4885SCD 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.